A review of the clinical consequences of variation in thyroid function within the reference range

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages 3562-3571

  Taylor, Peter N ^a   Razvi, Salman ^b   Pearce, Simon H ^c   Dayan, Colin M ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b GATESHEAD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; THYROID HORMONE; THYROTROPIN;

BODY MASS; BODY WEIGHT; BONE DENSITY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; DISEASE ASSOCIATION; FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTHYROIDISM; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NEUROLOGY; OUTCOME ASSESSMENT; PATIENT MONITORING; PREGNANCY OUTCOME; PRIORITY JOURNAL; PSYCHOLOGY; REFERENCE VALUE; REVIEW; RISK BENEFIT ANALYSIS; THYROID DISEASE; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; BLOOD; FEMALE; MALE; PATHOPHYSIOLOGY; PREGNANCY; RISK FACTOR; THYROID GLAND;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY OUTCOME; REFERENCE VALUES; RISK FACTORS; THYROID DISEASES; THYROID GLAND; THYROID HORMONES;

EID: 84883729865     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1315     Document Type: Review

References (83)

1. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012; 379:1142-1154.
2. Roberts CG, Ladenson PW. Hypothyroidism. Lancet. 2004;363: 793-803.
3. Cooper DS. Hyperthyroidism. Lancet. 2003;362:459-468.
4. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76-131.
5. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534.
6. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499.
7. Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE. National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction. J Clin Endocrinol Metab. 2007;92:4236-4240.
8. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
9. McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab. 2001;86:4585-4590.
10. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab. 2001;86:4591-4599.
11. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005;90: 5483-5488.
12. Surks MI,GoswamiG, DanielsGH.The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab. 2005;90: 5489-5496.
13. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-Aged patients. J Clin Endocrinol Metab. 2000;85:4701-4705.
14. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults.JAMA. 2006;295:1033-1041.
15. DaneseMD,PoweNR,Sawin CT, LadensonPW.Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA. 1996;276:285-292.
16. Ochs N, Auer R, Bauer DC, et al. Meta-Analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148:832-845.
17. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988-1028.
18. McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011;21:837-843.
19. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
20. Iqbal A, Figenschau Y, Jorde R. Blood pressure in relation to serum thyrotropin: the Tromso study. J Hum Hypertens. 2006;20:932-936.
21. Asvold BO, Bjoro T, Nilsen TI, Vatten LJ. Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based study. J Clin Endocrinol Metab. 2007;92:841-845.
22. Ittermann T, Thamm M, Wallaschofski H, Rettig R, Volzke H. Serum thyroid-stimulating hormone levels are associated with blood pressure in children and adolescents. J Clin Endocrinol Metab. 2012;97:828-834.
23. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. TheHUNTStudy. Eur J Endocrinol. 2007; 156:181-186.
24. Lee YK, Kim JE, Oh HJ, et al. Serum TSH level in healthy Koreans and the association of TSH with serum lipid concentration and metabolic syndrome. Korean J Intern Med. 2011;26:432-439.
25. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.NEngl J Med. 1993;328: 914-921.
26. Pearce SH, Vaisman M, Wemeau JL. Management of subclinical hypothyroidism: the thyroidologists' view. Eur Thyroid J. 2012;1: 45-50.
27. Asvold BO, Bjoro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: theHUNTstudy. Arch Intern Med. 2008;168:855-860.
28. Asvold BO, Bjoro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of theHUNTstudy in Norway. Clin Endocrinol (Oxf). 2012;77:911-917.
29. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95: 186-193.
30. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126: 1040-1049.
31. Iida M, Yamamoto M, Ishiguro Y, Yamazaki M, Honjo H, Kamiya K. Thyroid hormone within the normal range is associated with left ventricular mass in patients with hypertension. JAmSoc Hypertens. 2012;6:261-269.
32. Kim ES, Shin JA, Shin JY, et al. Association between low serum free thyroxine concentrations and coronary artery calcification in healthy euthyroid subjects. Thyroid. 2012;22:870-876.
33. Ertas F, Kaya H, Soydinc MS. Low serum free triiodothyronine levels are associated with the presence and severity of coronary artery disease in the euthyroid patients: an observational study. Anadolu Kardiyol Derg. 2012;12:591-596.
34. Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005;90:4019-4024.
35. Asvold BO, Bjoro T, Vatten LJ. Association of serumTSHwith high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab. 2009;94:5023-5027.
36. Fox CS, Pencina MJ, D'Agostino RB, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med. 2008;168: 587-592.
37. Svare A, Nilsen TI, Bjoro T, Asvold BO, Langhammer A. Serum TSH related to measures of body mass: longitudinal data from the HUNT Study, Norway. Clin Endocrinol (Oxf). 2011;74:769-775.
38. Ruhla S, Weickert MO, Arafat AM, et al. A high normal TSH is associated with the metabolic syndrome. Clin Endocrinol (Oxf). 2010;72:696-701.
39. Prats-Puig A, Sitjar C, Ribot R, et al. Relative hypoadiponectinemia, insulin resistance, and increased visceral fat in euthyroid prepubertal girls with low-normal serum free thyroxine. Obesity (Silver Spring). 2012;20:1455-1461.
40. Bassols J, Prats-Puig A, Soriano-Rodriguez P, et al. Lower free thyroxin associates with a less favorable metabolic phenotype in healthy pregnant women. J Clin Endocrinol Metab. 2011;96:3717-3723.
41. Asvold BO, Bjoro T, Vatten LJ. Association of thyroid function with estimated glomerular filtration rate in a population-based study: the HUNT study. Eur J Endocrinol. 2011;164:101-105.
42. den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol (Oxf). 2005;62:423-427.
43. Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159:79-82.
44. HannaFW,ScanlonMF.Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet. 1997;350:755-756.
45. Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. Am J Med. 1978;64:613-621.
46. Morris MS. The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone. 2007;40:1128-1134.
47. Murphy E, Gluer CC, Reid DM, et al. Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab. 2010;95:3173-3181.
48. Kim BJ, Lee SH, Bae SJ, et al. The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men. Clin Endocrinol (Oxf). 2010;73:396-403.
49. Kim DJ, Khang YH, Koh JM, Shong YK, Kim GS. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol (Oxf). 2006;64:86-90.
50. van der Deure WM, Uitterlinden AG, Hofman A, et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf). 2008; 68:175-181.
51. Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A. SerumTSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone. 2010;46:747-751.
52. La Vignera S, Vicari E, Tumino S, et al. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history. Minerva Ginecol. 2008;60:475-484.
53. Roef G, Lapauw B, Goemaere S, et al. Thyroid hormone status within the physiological range affects bone mass and density in healthy men at the age of peak bone mass. Eur J Endocrinol. 2011; 164:1027-1034.
54. Rosen CJ. Pathogenesis of osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:181-193.
55. Pop VJ, Kuijpens JL, van Baar AL, et al.Lowmaternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf). 1999; 50:149-155.
56. Panicker V, Evans J, Bjoro T, Asvold BO, Dayan CM, Bjerkeset O. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol (Oxf). 2009;71:574-580.
57. Alvarez-Pedrerol M, Ribas-Fito N, Torrent M, Julvez J, Ferrer C, Sunyer J. TSH concentration within the normal range is associated with cognitive function andADHDsymptoms in healthy preschoolers. Clin Endocrinol (Oxf). 2007;66:890-898.
58. Hoshiko S, Grether JK, Windham GC, Smith D, Fessel K. Are thyroid hormone concentrations at birth associated with subsequent autism diagnosis? Autism Res. 2011;4:456-463.
59. Eskelinen SI, Vahlberg TJ, Isoaho RE, Lopponen MK, Kivela SL, Irjala KM. Associations of thyroid-stimulating hormone and free thyroxine concentrations with health and life satisfaction in elderly adults. Endocr Pract. 2007;13:451-457.
60. van Boxtel MP, Menheere PP, Bekers O, Hogervorst E, Jolles J. Thyroid function, depressed mood, and cognitive performance in older individuals: the Maastricht Aging Study. Psychoneuroendocrinology. 2004;29:891-898.
61. Wahlin A, Wahlin TB, Small BJ, Backman L. Influences of thyroid stimulating hormone on cognitive functioning in very old age. J Gerontol B Psychol Sci Soc Sci. 1998;53:P234-P239.
62. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591-2599.
63. Williams MD, Harris R, Dayan CM, Evans J, Gallacher J, Ben- Shlomo Y. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a metaanalysis. Clin Endocrinol (Oxf). 2009;70:484-492.
64. Berlin I, Payan C, Corruble E, Puech AJ. Serum thyroid-stimulatinghormone concentration as an index of severity of major depression. Int J Neuropsychopharmacol. 1999;2:105-110.
65. Joffe RT, Levitt AJ. Basal thyrotropin and major depression: relation to clinical variables and treatment outcome. Can J Psychiatry. 2008;53:833-838.
66. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro- Green A. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab. 2010;95:E44-E48.
67. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro- Green A. Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. J Clin Endocrinol Metab. 2010;95:1699-1707.
68. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-1125.
69. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97:2543-2565.
70. Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012;366: 493-501.
71. Hellevik AI, Asvold BO, Bjoro T, Romundstad PR, Nilsen TI, Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev. 2009;18:570-574.
72. Asvold BO, Bjoro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med. 2007; 167:1428-1432.
73. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861-865.
74. Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87:1068-1072.
75. Taylor PN, Panicker V, Sayers A, et al. A meta-Analysis of the associations between common variation in the PDE8B gene and thyroid hormone parameters, including assessment of longitudinal stability of associations over time and effect of thyroid hormone replacement. Eur J Endocrinol. 2011;164:773-780.
76. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, DayanCM.Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577-585.
77. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623-1629.
78. Meulenbelt I, Min JL, Bos S, et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet. 2008;17:1867-1875.
79. Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract. 1993;43:107-109.
80. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a meta-Analysis. J Clin Endocrinol Metab. 2008;93:2998-3007.
81. Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med. 2012;172:811-817.
82. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3-126.
83. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality.JAMA. 2010;304:1365-1374.